We have revised our recommendation on Novo Nnordisk, following the updates at the capital markets day and the approval of its block-buster potential GLP-1 candidate Ozempic (semaglutide). Although the announcements in CMD are just plans and the investment case rests on execution, the direction and activeness look positive to us. The quality of execution could also provide a further reason for upgrading the estimates in the future.
28 Dec 2017
Sneak peek into the future: sunny outlook
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sneak peek into the future: sunny outlook
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
28 Dec 2017 -
Author:
Kamla Singh -
Pages:
4
We have revised our recommendation on Novo Nnordisk, following the updates at the capital markets day and the approval of its block-buster potential GLP-1 candidate Ozempic (semaglutide). Although the announcements in CMD are just plans and the investment case rests on execution, the direction and activeness look positive to us. The quality of execution could also provide a further reason for upgrading the estimates in the future.